Migratory flow and hepatitis delta infection in Italy: A new challenge at the beginning of the third millennium.

Abstract:

:In Italy, HDV infection endemicity has greatly decreased overtime. Migratory flow may change this scenario as migrants often come from high HDV endemicity areas. Here, we studied characteristics of HDV infection in Italy, particularly addressed to the birth area of subjects. Chronic HBsAg carriers consecutively referring to 9 units in Italy prospectively enrolled for a six-month period in 2019 were tested for anti-HDV by ELISA. Multiple logistic regression analysis was performed to identify anti-HDV positivity independent predictors. A total of 894 HBsAg-positive subjects were enrolled. Of them, 786 (87.9%) were tested for anti-HDV. Anti-HDV overall prevalence was 9.9% (6.4% in Italian natives and 26.4% in non-natives; P < .001). HDV-RNA was checked in 63 (80.8%) of the 78 anti-HDV+ subjects, and 49 (77.8%) tested positive. Compared to non-natives, Italians were more likely males (male/female 1.6 vs 0.6; P < .05) and older (median age 57 years vs 46 years; P < .05). Multivariate analysis showed that non-natives (OR = 6.02; CI 95% = 3.06-11.84) and cirrhosis (OR 9.6; CI 95% = 5.39-17.30) were independently associated with anti-HDV positivity. A remarkable changing pattern in some characteristics of anti-HDV-positive subjects was observed over 1987-2019: a decreasing male/female ratio, an increasing mean age and proportion of cirrhotic subjects. Anti-HDV prevalence decreased from 7.4% to 6.4% among Italians, increasing from 12.2% to 26.4% among non-natives during 2001-2019. Hence, HDV infection in Italians is further decreasing and mostly affects old people and subjects with advanced disease reflecting a survival effect. Conversely, non-natives are sixfold more likely anti-HDV-positive with an increasing trend. Migratory flow may be a new challenge for HDV infection at the beginning of the third millennium.

journal_name

J Viral Hepat

authors

Stroffolini T,Ciancio A,Furlan C,Vinci M,Fontana R,Russello M,Colloredo G,Morisco F,Coppola N,Babudieri S,Ferrigno L,Sagnelli C,Sagnelli E

doi

10.1111/jvh.13310

subject

Has Abstract

pub_date

2020-09-01 00:00:00

pages

941-947

issue

9

eissn

1352-0504

issn

1365-2893

journal_volume

27

pub_type

杂志文章
  • Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.

    abstract::To evaluate the cost-effectiveness of ledipasvir/sofosbuvir (LDV/SOF) in treatment-naïve patients with chronic hepatitis C (CHC) genotype 1 (GT1) in the absence or mild fibrosis (F0-F1) versus advanced fibrosis (F2-F4), from the perspective of the Spanish Health System. A Markov model was developed to simulate disease...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12704

    authors: Buti M,Domínguez-Hernández R,Oyagüez I,Casado MA,Esteban R

    更新日期:2017-09-01 00:00:00

  • Frequency and clinical outcomes of flares related to nucleos(t)ide analogue therapy in patients with chronic hepatitis B.

    abstract::Flares in chronic hepatitis B are often detrimental but sometimes lead to sustained immune control and disease remission. The aim of this study was to estimate the frequency of hepatitis flares which occur during and/or after cessation of nucleos(t)ide analogue (NA) therapy, and to assess their outcomes. In a single c...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01448.x

    authors: Zhang NP,Reijnders JG,Perquin M,Hansen BE,Janssen HL

    更新日期:2011-07-01 00:00:00

  • High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme.

    abstract::To achieve WHO hepatitis C virus (HCV) elimination targets by 2030, mathematical models suggest there needs to be significant scale-up of treatment among people who inject drugs (PWID). We tested whether people who actively inject drugs can be recruited and treated successfully through a community needle and syringe p...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13035

    authors: Schulkind J,Stephens B,Ahmad F,Johnston L,Hutchinson S,Thain D,Ward Z,Vickerman P,Hickman M,Dillon JF

    更新日期:2019-05-01 00:00:00

  • New HBV subgenotype D9, a novel D/C recombinant, identified in patients with chronic HBeAg-negative infection in Eastern India.

    abstract::Genome diversity is a hallmark of hepatitis B virus (HBV), which allowed its classification into 10 genotypes (A-J) and numerous subgenotypes. Among them, Genotype D is currently segregated into eight subgenotypes (D1-D8). Here, we report the identification and characterization of a novel subgenotype within genotype D...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2012.01655.x

    authors: Ghosh S,Banerjee P,Deny P,Mondal RK,Nandi M,Roychoudhury A,Das K,Banerjee S,Santra A,Zoulim F,Chowdhury A,Datta S

    更新日期:2013-03-01 00:00:00

  • How will we manage acute HCV in men having sex with men in the era of all oral therapy?

    abstract::With the advent of direct-acting antivirals (DAAs), the treatment of chronic hepatitis C virus (HCV) infection (CHC) has been revolutionized. Modern interferon- and potentially also ribavirin-free combinations consisting of 2 or 3 direct-acting antivirals (DAA) promise sustained virological response rates (SVR) of abo...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/jvh.12348

    authors: Boesecke C,Rockstroh JK

    更新日期:2015-01-01 00:00:00

  • In vivo infectivity of liver extracts after resolution of hepadnaviral infection following therapy associating DNA vaccine and cytokine genes.

    abstract::DNA-based vaccination appears of promise for chronic hepatitis B immunotherapy, although there is an urgent need to increase its efficacy. In this preclinical study, we evaluated the therapeutic benefit of cytokine (IL-2, IFN-γ) genes co-delivery with DNA vaccine targeting hepadnaviral proteins in the chronic duck hep...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12023

    authors: Saade F,Buronfosse T,Guerret S,Pradat P,Chevallier M,Zoulim F,Jamard C,Cova L

    更新日期:2013-04-01 00:00:00

  • Clinical characteristics and long-term outcome of acute kidney injury in patients with HBV-related acute-on-chronic liver failure.

    abstract::Acute kidney injury (AKI) is a common complication in patients with decompensated cirrhosis and is also an important cause for poor outcome. This study aimed at investigating the clinical characteristics and long-term prognosis of AKI in patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACL...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12566

    authors: Shi X,Zhu P,Yan G,Liu C,Zhang C,Huang G,Zhang Y,Yan Z,Wang Y

    更新日期:2016-11-01 00:00:00

  • A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.

    abstract::We determined whether triple therapy comprising amantadine (AMA), ribavirin (RBV) and either peginterferon (PEG-IFN) alpha-2a or conventional IFN alpha-2a would improve sustained virological response (SVR) rates over dual therapy with IFN alpha-2a and RBV in patients with chronic HCV infection. A total of 362 treatmen...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2893.2005.00591.x

    authors: Mangia A,Ricci GL,Persico M,Minerva N,Carretta V,Bacca D,Cela M,Piattelli M,Annese M,Maio G,Conte D,Guadagnino V,Pazienza V,Festi D,Spirito F,Andriulli A

    更新日期:2005-05-01 00:00:00

  • Study on the function of circulating plasmacytoid dendritic cells in the immunoactive phase of patients with chronic genotype B and C HBV infection.

    abstract::Hepatitis B virus (HBV) infection induces a wide range of chronic liver injury. The mechanism by which HBV evades the immune surveillance system remains obscure. Plasmacytoid dendritic cells (pDCs) seem to be the major endogenous interferon (IFN)-alpha producers and represent one of the most important cell types in th...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2006.00819.x

    authors: Wang K,Fan X,Fan Y,Wang B,Han L,Hou Y

    更新日期:2007-04-01 00:00:00

  • Estimating paediatric hepatitis C prevalence in the United States.

    abstract::Over 70 million individuals are infected with hepatitis C virus (HCV) worldwide. Yet most prevalence data are in the adult population, with little focus on paediatrics, partially due to the scarcity of public data. The objective of this paper is to examine HCV prevalence in children by estimating prevalence rates amon...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13377

    authors: Rahal H,Boutros S,Farhat M,Kullar R,Rahal K,Saab S

    更新日期:2020-12-01 00:00:00

  • Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection.

    abstract::Hepatitis E virus (HEV) represents one of the foremost causes of acute hepatitis globally. Although there is no proven medication for hepatitis E, pegylated interferon-α (IFN-α) has been used as off-label drug for treating HEV. However, the efficacy and molecular mechanisms of how IFN signalling interacts with HEV rem...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12491

    authors: Zhou X,Xu L,Wang W,Watashi K,Wang Y,Sprengers D,de Ruiter PE,van der Laan LJ,Metselaar HJ,Kamar N,Peppelenbosch MP,Pan Q

    更新日期:2016-04-01 00:00:00

  • HCV burden of infection in Egypt: results from a nationwide survey.

    abstract::Egypt is the country with the largest hepatitis C virus (HCV) epidemic in the world. In 2008, a Demographic Health Survey (DHS) was carried out in Egypt, providing for the first time a unique opportunity for HCV antibody testing on a nationwide representative sample of individuals. Consenting individuals answered a qu...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01576.x

    authors: Guerra J,Garenne M,Mohamed MK,Fontanet A

    更新日期:2012-08-01 00:00:00

  • Do antiviral CD8+ T cells select hepatitis C virus escape mutants? Analysis in diverse epitopes targeted by human intrahepatic CD8+ T lymphocytes.

    abstract::Hepatitis C virus (HCV) is a variable RNA virus that can readily establish persistent infection. Cellular immune responses are important in the early control of the virus. Evidence from animal models suggests that mutation in epitopes recognized by CD8+ T lymphocytes may play an important role in the establishment of ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2005.00676.x

    authors: Komatsu H,Lauer G,Pybus OG,Ouchi K,Wong D,Ward S,Walker B,Klenerman P

    更新日期:2006-02-01 00:00:00

  • Metformin inhibits hepatitis B virus protein production and replication in human hepatoma cells.

    abstract::Hepatitis B virus surface antigen (HBsAg) plays an important role in maintaining the tolerance and may interfere with host innate and adaptive immune responses; therefore, novel therapeutic strategies to reduce HBsAg loads in patients infected with hepatitis B virus (HBV) are emerging as an attractive but challenging ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12187

    authors: Xun YH,Zhang YJ,Pan QC,Mao RC,Qin YL,Liu HY,Zhang YM,Yu YS,Tang ZH,Lu MJ,Zang GQ,Zhang JM

    更新日期:2014-08-01 00:00:00

  • Characterization of hepatitis B virus surface antigen variability and impact on HBs antigen clearance under nucleos(t)ide analogue therapy.

    abstract::For hepatitis B virus (HBV)-related chronic infection under treatment by nucleos(t)ide analogues (NUCs), HBsAg clearance is the ultimate therapeutic goal but very infrequent. We investigated how HBV envelope protein variability could lead to differential HBsAg clearance on NUCs. For 12 HBV genotype D patients receivin...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12498

    authors: Velay A,Jeulin H,Eschlimann M,Malvé B,Goehringer F,Bensenane M,Frippiat JP,Abraham P,Ismail AM,Murray JM,Combet C,Zoulim F,Bronowicki JP,Schvoerer E

    更新日期:2016-05-01 00:00:00

  • The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: Considerations for future novel therapeutics.

    abstract::Despite the availability of a preventative vaccine, chronic hepatitis B (CHB) remains a global healthcare challenge with the risk of disease progression due to cirrhosis and hepatocellular carcinoma. Although current treatment strategies, interferon and nucleos(t)ide analogues have contributed to reducing morbidity an...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/jvh.13040

    authors: Gill US,Kennedy PTF

    更新日期:2019-01-01 00:00:00

  • The expression of hepatitis B virus polymerase in hepatocytes during chronic HBV infection.

    abstract::A recombinant protein corresponding to part of the amino-terminal domain of hepatitis B virus (HBV) polymerase was expressed in Escherichia coli. Antisera raised against this protein stained hepatocytes, from human liver biopsies, predominantly in the nucleus but some cytoplasmic staining was also observed. No stainin...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.1996.tb00083.x

    authors: McGarvey MJ,Goldin RD,Karayiannis P,Thomas HC

    更新日期:1996-03-01 00:00:00

  • Modifications of plasma platelet-activating factor (PAF)-acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection.

    abstract::Hepatitis C virus (HCV) chronically infects about 200 million individuals worldwide and leads to severe liver and lymphatic diseases. HCV circulates in the serum, associated with apoB-containing lipoproteins. Platelet-activating factor (PAF), a pro-inflammatory mediator, is mainly modulated by plasma PAF-acetylhydrola...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2006.00766.x

    authors: Caini P,Guerra CT,Giannini C,Giannelli F,Gragnani L,Petrarca A,Solazzo V,Monti M,Laffi G,Zignego AL

    更新日期:2007-01-01 00:00:00

  • Anti-interferon-α neutralizing antibody is associated with nonresponse to pegylated interferon-α plus ribavirin in chronic hepatitis C.

    abstract::Pegylated interferon-α (PEG-IFN-α) plus ribavirin (RBV) treatment fails to achieve a sustained virological response (SVR) in approximately 20-50% of patients with chronic hepatitis C virus (HCV) infection. We assessed the contribution of an anti-IFN-α neutralizing antibody (NAb) on the nonresponse to treatment. NAbs w...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2012.01598.x

    authors: Matsuda F,Torii Y,Enomoto H,Kuga C,Aizawa N,Iwata Y,Saito M,Imanishi H,Shimomura S,Nakamura H,Tanaka H,Iijima H,Tsutsui H,Tanaka Y,Nishiguchi S

    更新日期:2012-10-01 00:00:00

  • Methamphetamine enhances Hepatitis C virus replication in human hepatocytes.

    abstract::Very little is known about the interactions between hepatitis C virus (HCV) and methamphetamine, which is a highly abused psychostimulant and a known risk factor for human immunodeficiency virus (HIV)/HCV infection. This study examined whether methamphetamine has the ability to inhibit innate immunity in the host cell...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2007.00940.x

    authors: Ye L,Peng JS,Wang X,Wang YJ,Luo GX,Ho WZ

    更新日期:2008-04-01 00:00:00

  • Lower serum viral loads in young patients with hepatitis-B-virus-related hepatocellular carcinoma.

    abstract::Advanced age and high hepatitis B virus (HBV) DNA level are risk factors associated with the development of HBV-related hepatocellular carcinoma (HCC). However, little is known about the role of viral load in the carcinogenesis of HCC in young people. A total of 183 HBV-related HCC patients and 202 HBV carriers were t...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2006.00780.x

    authors: Tsai FC,Liu CJ,Chen CL,Chen PJ,Lai MY,Kao JH,Chen DS

    更新日期:2007-03-01 00:00:00

  • Exposure to hepatitis B and C of tattooists in Victoria in 1984.

    abstract::Although tattooing is recognized as a risk factor for transmission of hepatitis C, the efficiency with which transmission occurs is unknown. Sera stored from a serosurvey of tattooists undertaken in 1984 to test for human immunodeficiency virus (HIV) provided the opportunity to determine the prevalence of serological ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.1997.tb00216.x

    authors: Thompson SC,Goudey RE,Breschkin AM,Carnie J,Catton M

    更新日期:1997-03-01 00:00:00

  • Imbalance between cytoproliferation and apoptosis in hepatitis C virus related chronic liver disease.

    abstract::An imbalance between cytoproliferation and apoptosis may be relevant in liver carcinogenesis. The aim of this study was to analyse these parameters in patients with chronic liver damage in relation to the aetiology of the disease. Forty-eight patients were studied: 23 had hepatitis C virus (HCV)- and 11 had hepatitis ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2001.00267.x

    authors: Farinati F,Cardin R,Fiorentino M,D'errico A,Grigioni W,Cecchetto A,Naccarato R

    更新日期:2001-01-01 00:00:00

  • Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region.

    abstract::Treatment of chronic hepatitis B has been greatly improved by the use of lamivudine, but mutations occur in the polymerase region of hepatitis B virus (HBV) and lamivudine-resistant mutants frequently develop. The emergence of lamivudine-resistant strains of HBV is a problem for treating chronic hepatitis B using lami...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2005.00559.x

    authors: Natsuizaka M,Hige S,Ono Y,Ogawa K,Nakanishi M,Chuma M,Yoshida S,Asaka M

    更新日期:2005-03-01 00:00:00

  • Semiquantitative assessment of IgM antibody to hepatitis B core antigen and prediction of the severity of chronic hepatitis B.

    abstract::Controversial results have been reported concerning the correlation between serum levels of IgM antibodies to hepatitis B core antigen (IgM HBcAb) and the histological activity of chronic hepatitis B. In this study, paired serum samples and liver biopsies were collected from 200 consecutive chronic hepatitis B patient...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.1999.00171.x

    authors: Colloredo G,Bellati G,Sonzogni A,Zavaglia C,Fracassetti O,Leandro G,Ghislandi R,Minola E,Ideo G

    更新日期:1999-11-01 00:00:00

  • Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study.

    abstract::The objectives of this study were to investigate the prevalence of infections with hepatotrophic viruses in an anti-human immunodeficiency virus (HIV)-positive population from Buenos Aires and to compare it among the main risk groups for HIV infection. Four hundred and eighty-four consecutive patients attending the HI...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究

    doi:10.1046/j.1365-2893.1999.t01-1-6120135.x

    authors: Fainboim H,González J,Fassio E,Martínez A,Otegui L,Eposto M,Cahn P,Marino R,Landeira G,Suaya G,Gancedo E,Castro R,Brajterman L,Laplumé H

    更新日期:1999-01-01 00:00:00

  • Long-term interferon-alpha treatment of children with chronic hepatitis delta: a multicentre study.

    abstract::We assessed the efficacy of prolonged interferon-alpha (IFN) therapy in children with chronic hepatitis caused by hepatitis delta virus (HDV) by treating 26 paediatric cases with IFN-alpha 2b (5 MU m-2, then 3 MU m-2 three times weekly for 12 (medium-term group MTG) or 24 months (long-term group, LTG). Compliance and ...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1111/j.1365-2893.1996.tb00002.x

    authors: Di Marco V,Giacchino R,Timitilli A,Bortolotti F,Crivellaro C,Calzia R,Iannuzzi C,Prestileo T,Vajro P,Nebbia G,Stringhi C,Rosina F,Biassoni D,Callea F,Rizzetto M,Craxi A

    更新日期:1996-05-01 00:00:00

  • Hepatitis B virus mother-to-child transmission among HIV-infected women receiving lamivudine-containing antiretroviral regimens during pregnancy and breastfeeding.

    abstract::The study included 309 HIV-infected pregnant women receiving a lamivudine-containing antiretroviral regimen from week 25 of gestational age until 6 months postpartum, during breastfeeding. Twenty-seven of them (8.7%) were hepatitis B virus surface antigen (HBsAg) positive; at baseline, hepatitis B virus (HBV) DNA leve...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12301

    authors: Pirillo MF,Scarcella P,Andreotti M,Jere H,Buonomo E,Sagno JB,Amici R,Mancini MG,Leone P,Ceffa S,Mancinelli S,Marazzi MC,Vella S,Palombi L,Giuliano M

    更新日期:2015-03-01 00:00:00

  • Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients.

    abstract::To assess the impact of sequential therapy with adefovir dipivoxil (ADV) and pegylated interferon alfa-2a (PEG-IFN) on virological (serum HBV-DNA) and serological (serum HBsAg) response in 20 consecutive HBeAg-negative patients. Patients received ADV for 20 weeks, then ADV and PEG-IFN for 4 weeks and lastly PEG-IFN fo...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2893.2010.01332.x

    authors: Moucari R,Boyer N,Ripault MP,Castelnau C,Mackiewicz V,Dauvergne A,Valla D,Vidaud M,Chanoine MH,Marcellin P

    更新日期:2011-08-01 00:00:00

  • An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.

    abstract:SUMMARY:Noninvasive markers that accurately follow changes in fibrosis may provide alternatives to liver biopsy for assessment of histological endpoints of antiviral therapy in chronic hepatitis C (CHC). This study compared two commercially available serum marker panels (HCV FibroSURE and FIBROSpect II) during interfer...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2893.2008.01062.x

    authors: Patel K,Benhamou Y,Yoshida EM,Kaita KD,Zeuzem S,Torbenson M,Pulkstenis E,Subramanian GM,McHutchison JG

    更新日期:2009-03-01 00:00:00